Intravenous ferric carboxymaltose in iron-Deficient chronic heart failure patients with and without anaemia: A subanalysis of the FAIR-HF trial

European Journal of Heart Failure

Volumn 15, Issue 11, 2013, Pages 1267-1276

  Filippatos, Gerasimos ^a   Farmakis, Dimitrios ^a   Colet, Josep Comin ^b,c   Dickstein, Kenneth ^d,e   Lüscher, Thomas F ^f   Willenheimer, Ronnie ^g,h   Parissis, John ^a   Gaudesius, Giedrius ⁱ   Mori, Claudio ⁱ   Rothe, Barbara Von Eisenhart ⁱ   Greenlaw, Nicola ^j   Ford, Ian ^j   Ponikowski, Piotr ^k   Anker, Stefan D ^l,m  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g Heart Health Group   (Sweden)

^h LUND UNIVERSITY   (Sweden)

ⁱ Vifor (International) Inc   (Switzerland)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k WROCLAW MEDICAL UNIVERSITY   (Poland)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m IRCCS SAN RAFFAELE PISANA   (Italy)

more..

Author keywords

Anaemia; Ferric carboxymaltose; Heart failure; Intravenous iron; Iron deficiency

Indexed keywords

FERRIC CARBOXYMALTOSE; HEMOGLOBIN; PLACEBO;

ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEATH; DISTANCE PERCEPTION; DRUG EFFICACY; DRUG SAFETY; EUROPEAN QUALITY OF LIFE 5 DIMENSION; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART FAILURE; HOSPITALIZATION; HUMAN; INFESTATION; INJECTION SITE INFECTION; IRON DEFICIENCY; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROLOGIC DISEASE; NEW YORK HEART ASSOCIATION CLASS; PATIENT GLOBAL ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SELF REPORT; THORAX DISEASE; VASCULAR DISEASE; VISUAL ANALOG SCALE;

ANAEMIA; FERRIC CARBOXYMALTOSE; HEART FAILURE; INTRAVENOUS IRON; IRON DEFICIENCY;

ADMINISTRATION, INTRAVENOUS; AGED; ANEMIA, IRON-DEFICIENCY; CASE-CONTROL STUDIES; CHRONIC DISEASE; DEFICIENCY DISEASES; FEMALE; FERRIC COMPOUNDS; HEART FAILURE; HEMATINICS; HUMANS; IRON; MALE; MALTOSE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84890044082     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft099     Document Type: Article

References (38)

1. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-827
2. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454-2461
3. Anand IS. Pathophysiology of anemia in heart failure. Heart Fail Clin 2010;6:279-288
4. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48:2485-2489
5. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetinalfa in systolic heart failure. N Engl J Med 2013;368:1210-1219
6. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure Eur Heart J 2010;31:1872-1880
7. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Mori C, von Eisenhart Rothe B, Pocock S, Poole-Wilson PA, Ponikowski P; FAIR-HF committees and investigators. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009;11:1084-1091
8. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448
9. OkonkoDO,Grzeslo A, WitkowskiT, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51:103-112
10. GreenCP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-1255
11. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-343
12. McCullagh P. Regression models for ordinal data. J R Stat Soc B 1980;42:109-142
13. Ezekowitz JA, McAlister FA, ArmstrongPW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107:223-225
14. Aessopos A, Deftereos S, Farmakis D, Corovesis C, Tassiopoulos S, Tsironi M, Georgonikou D, Moyssakis J. Cardiovascular adaptation to chronic anemia in the elderly: an echocardiographic study. Clin Invest Med 2004;27:265-273
15. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004;44:959-966
16. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-1744
17. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-299
18. Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, Filippatos G, Kremastinos DT. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008;155:751.e1-e7
19. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007;28:2208-2216
20. van der Meer P, Groenveld HF, Januzzi JL Jr, van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009;95: 1309-1314
21. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S,Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098
22. Pfeffer MA, Burdmann EA, ChenCY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032
23. de Silva R, Rigby AS, Witte KK, Nikitin NP, Tin L, Goode K, Bhandari S, Clark AL, Cleland JG. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 2006;98:391-398
24. Zhu Y, Haas J. Altered metabolic response of iron-depleted non-anemic women during a 15-km time trial. J Appl Physiol 1998;84:1768-1775
25. Brownlie T, Utermohlen V, Hinton P, Giordano C, Haas J. Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. Am J Clin Nutr 2002;75:734-742
26. Haas JD, Brownlie T 4th. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001;131(2S-2): 676S-688S
27. Ohira Y, Edgerton VR, GardnerGW, Senewiratne B, Barnard RJ, Simpson DR.Work capacity, heart rate and blood lactate responses to iron treatment. Br J Haematol 1979;41:365-372
28. Hinton P, Giordano C, Brownlie T, Haas J. Iron supplementation improves endurance after training in iron-depleted, non-anemic women. J Appl Physiol 2000;88: 1103-1111
29. De'tivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, Ropert M, Jacquelinet S, Courselaud B, Ganz T, Brissot P, Lore'al O. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005;106:746-748
30. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 2005;26:2368-2374
31. Silverberg DS. The role of erythropoiesis stimulating agents and intravenous (4) iron in the cardio renal anemia syndrome. Heart Fail Rev 2011;16:609-614
32. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352: 1011-1023
33. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012;1823: 1434-1443
34. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ. 2011 Update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia. Med J Aust 2011;194: 405-409
35. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Lüscher TF,Mori C, Willenheimer R, Ponikowski P, Anker SD. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J 2013;34:30-38
36. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, NielsenOW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-869
37. EFFECT-HF. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure. http://clinicaltrials. gov/ct2/show/NCT01394562 (9 September 2012)
38. CONFIRM-HF.Astudy to compare the use of ferric carboxymaltose with placebo in patients with chronic heart failure and iron deficiency. http://clinicaltrials.gov/ct2/show/NCT01453608?term=confirm-hf&rank=1 (9 September 2012)